The influence of Duffy blood group on renal allograft outcome in african americans

Publisher Website
Google Scholar
Abstract
Background. African American patients demonstrate higher rates of acute allograft rejection and lower kidney-graft survival compared with white patients. Duffy antigen receptor for chemokines (DARC) on red blood cells has been suggested to have an anti-inflammatory role by acting as a “chemokine sink.” We investigated the relationship of Duffy blood group type to renal allograft outcome in African American patient population. Methods. A total of 163 African American kidney-transplant recipients were studied for Duffy blood group status. Patient outcomes were assessed at 6 to 42 months after transplantation and monitored for acute rejection episodes, graft function, and graft survival. Results. A total of 117 (71.8%) patients were Duffy (a−b−), 14 (8.6%) Duffy (a+b−), 21 (12.9%) Duffy (a−b+), and 11 (6.8%) Duffy (a+b+). No significant differences were observed among the groups with respect to median serum-creatinine values or the incidence of biopsy-confirmed acute-rejection episodes. Although only 15.4% of the patients had Duffy (a +) antigen, none lost their allograft during the study period, and Kaplan-Meier graft survival was not significantly different compared to Duffy (a−) group (log-rank test, P =0.12). Duffy (a−b−) patients demonstrated lower allograft survival compared with the other three groups, although statistical significance was not reached (log-rank test P =0.15). Delayed graft function (DGF) was strongly associated with graft failure for only Duffy (a−b−) patients (log-rank test P =0.003). Conclusions. Duffy (a−b−) patients have lower allograft survival in the presence of DGF. DARC may attenuate the inflammatory effects of DGF by acting as a “chemokine sink,” and DARC-negative patients may be more vulnerable to DGF.